一种用于早期检测高级别浆液性卵巢癌的新型多生物标志物组合
研究在172例健康、良性妇科疾病或高级别浆液性卵巢腺癌患者的血清样本中检测12种生物标志物,发现由CA125、HE4、E-CAD和IL-6组成的4标志物组合区分早期卵巢癌与非癌对照的ROC曲线下面积达0.961,优于CA125单用、HE4单用及CA125+HE4两标志物组合。
要点
- 4标志物组合(CA125、HE4、E-CAD、IL-6)区分早期卵巢癌与非癌对照的AUC为0.961。
- 该组合AUC优于CA125单用(0.851,P=0.0150)和HE4单用(0.870,P=0.0220)。
- 该组合AUC亦优于CA125+HE4两标志物组合(0.922,P=0.0278)。
核心结论
- 由CA125、HE4、E-CAD和IL-6组成的4标志物组合在检测早期浆液性卵巢癌方面显示出潜力。
- 作者认为有必要在卵巢癌患者中对该生物标志物组合进行进一步验证研究。
研究设计与样本
- 研究选取12种具有高差异基因表达且有验证抗体的血清生物标志物:IL-1Ra、IL-6、Dkk-1、uPA、E-CAD、ErbB2、SLPI、HE4、CA125、LCN2、MSLN和OPN。
- 使用Simple Plex™多分析物免疫测定平台检测172例患者采集的样本,患者为健康、患良性妇科疾病或患高级别浆液性卵巢腺癌。
- 获取受试者工作特征(ROC)曲线、ROC曲线下面积(AUC)及AUC的标准误(SE),并进行单变量ROC分析及多生物标志物联合的多变量ROC分析。
主要发现
- 由CA125、HE4、E-CAD和IL-6组成的4标志物组合具有最高的ROC AUC。
- 在区分早期卵巢癌与非癌对照时,4标志物组合AUC=0.961,优于CA125单用AUC=0.851(P=0.0150)和HE4单用AUC=0.870(P=0.0220)。
- 4标志物组合AUC=0.961亦显著优于CA125+HE4两标志物组合AUC=0.922(P=0.0278)。
- 在其ROC曲线下对应于特异度从100%降至约95%的区域,4标志物组合具有最高的平均灵敏度。
局限性
- 作者认为有必要在卵巢癌患者中对该生物标志物组合进行进一步验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Since the majority of patients are diagnosed at an advanced stage, ovarian cancer remains the most lethal gynecologic malignancy. There is no single biomarker with the sensitivity and specificity required for effective cancer screening; therefore, we investigated a panel of novel biomarkers for the early detection of high-grade serous ovarian carcinoma. METHODS: Twelve serum biomarkers with high differential gene expression and validated antibodies were selected: IL-1Ra, IL-6, Dkk-1, uPA, E-CAD, ErbB2, SLPI, HE4, CA125, LCN2, MSLN, and OPN. They were tested using Simple Plex™, a multi-analyte immunoassay platform, in samples collected from 172 patients who were either healthy, had benign gynecologic pathologies, or had high-grade serous ovarian adenocarcinomas. The receiver operating characteristic (ROC) curve, ROC area under the curve (AUC), and standard error (SE) of the AUC were obtained. Univariate ROC analyses and multivariate ROC analyses with the combination of multiple biomarkers were performed. RESULTS: The 4-marker panel consisting of CA125, HE4, E-CAD, and IL-6 had the highest ROC AUC. When evaluated for the ability to distinguish early stage ovarian cancer from a non-cancer control, not only did this 4-marker panel (AUC=0.961) performed better than CA 125 alone (AUC=0.851; P=0.0150) and HE4 alone (AUC=0.870; P=0.0220), but also performed significantly better than the 2- marker combination of CA125+HE4 (AUC=0.922; P=0.0278). The 4-marker panel had the highest average sensitivity under the region of its ROC curve corresponding to specificity ranging from 100% down to ~95%. CONCLUSION: The four-marker panel, CA125, HE4, E-CAD, and IL-6, shows potential in detecting serous ovarian cancer at earlier stages. Additional validation studies using the biomarker combination in ovarian cancer patients are warranted.
引用
- Han C, Bellone S, Siegel ER, et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol Oncol. 2018. PMID: 29572027. doi:10.1016/j.ygyno.2018.03.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。